[go: up one dir, main page]

DK4284387T3 - Nad-forstærkelsesterapi til parkinsons sygdom - Google Patents

Nad-forstærkelsesterapi til parkinsons sygdom Download PDF

Info

Publication number
DK4284387T3
DK4284387T3 DK22740800.2T DK22740800T DK4284387T3 DK 4284387 T3 DK4284387 T3 DK 4284387T3 DK 22740800 T DK22740800 T DK 22740800T DK 4284387 T3 DK4284387 T3 DK 4284387T3
Authority
DK
Denmark
Prior art keywords
nad
parkinson
disease
enhancement therapy
enhancement
Prior art date
Application number
DK22740800.2T
Other languages
English (en)
Inventor
Charalampos Tzoulis
Christian Dölle
Original Assignee
Vestlandets Innovasjonsselskap As Vis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=82492391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK4284387(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB2109138.4A external-priority patent/GB202109138D0/en
Application filed by Vestlandets Innovasjonsselskap As Vis filed Critical Vestlandets Innovasjonsselskap As Vis
Application granted granted Critical
Publication of DK4284387T3 publication Critical patent/DK4284387T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK22740800.2T 2021-06-24 2022-06-24 Nad-forstærkelsesterapi til parkinsons sygdom DK4284387T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2109138.4A GB202109138D0 (en) 2021-06-24 2021-06-24 NAD-augmentation Therapy for parkinson's disease
GBGB2200883.3A GB202200883D0 (en) 2021-06-24 2022-01-24 Nad-augmentation therapy for parkinson's disease
GR20220100277 2022-03-29
PCT/EP2022/067412 WO2022269066A1 (en) 2021-06-24 2022-06-24 Nad-augmentation therapy for parkinson's disease

Publications (1)

Publication Number Publication Date
DK4284387T3 true DK4284387T3 (da) 2024-09-02

Family

ID=82492391

Family Applications (1)

Application Number Title Priority Date Filing Date
DK22740800.2T DK4284387T3 (da) 2021-06-24 2022-06-24 Nad-forstærkelsesterapi til parkinsons sygdom

Country Status (10)

Country Link
US (1) US20240366648A1 (da)
EP (1) EP4284387B1 (da)
JP (1) JP2024524991A (da)
AU (1) AU2022299351B2 (da)
CA (1) CA3222399A1 (da)
DK (1) DK4284387T3 (da)
ES (1) ES2986075T3 (da)
FI (1) FI4284387T3 (da)
PL (1) PL4284387T3 (da)
WO (1) WO2022269066A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250275995A1 (en) * 2022-04-26 2025-09-04 Vestlandets Innovasjonsselskap As (Vis) Nicotinamide riboside dosage regimen for treating parkinson's disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0331620B1 (de) 1988-03-01 1993-08-11 Birkmayer, Walther, Prof. Dr. Mittel zur Behandlung des Parkinson-Syndroms
EP2574339A1 (de) 2011-09-27 2013-04-03 Johannes Huber Pharmazeutisches Präparat zur Behandlung von NADH-bedingten Erkrankungen
AU2017316614B2 (en) * 2016-08-22 2023-06-15 Elysium Health, Inc. Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders
WO2020257283A1 (en) * 2019-06-18 2020-12-24 Mitopower Llc Nicotinyl riboside compounds and their uses
WO2022028678A1 (en) * 2020-08-04 2022-02-10 Scandibio Therapeutics Ab Substances for treatment of neurological disorders

Also Published As

Publication number Publication date
EP4284387A1 (en) 2023-12-06
FI4284387T3 (fi) 2024-08-20
ES2986075T3 (es) 2024-11-08
JP2024524991A (ja) 2024-07-09
US20240366648A1 (en) 2024-11-07
CA3222399A1 (en) 2022-12-29
AU2022299351B2 (en) 2025-01-30
EP4284387B1 (en) 2024-07-31
WO2022269066A1 (en) 2022-12-29
AU2022299351A1 (en) 2024-01-04
PL4284387T3 (pl) 2024-11-25

Similar Documents

Publication Publication Date Title
PH12020551683A1 (en) Biomarkers for graft-versus-host disease
DK3906066T5 (da) Geneterapikonstruktioner til behandling af wilsons sygdom
EA201000644A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
BR112022003956A2 (pt) Anticorpos anti-cd73
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
EA201200507A1 (ru) Применение активаторов никотинового ацетилхолинового рецептора альфа 7
IL280315A (en) Methods of treatment and prevention of alzheimer's disease
DK3463351T3 (da) Behandling til parkinsons sygdom
IL309468A (en) Biomarkers for alzheimer's disease treatment
IL278813A (en) Gene therapy for Alzheimer's disease
IL292148A (en) Gene therapy for Alzheimer's disease
EA201891007A1 (ru) Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца
DOP2018000103A (es) Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona para tratar enfermedad de parkinson.
DK4284387T3 (da) Nad-forstærkelsesterapi til parkinsons sygdom
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
GB202016425D0 (en) Treatment regimens for parkinson's disease
IL280326A (en) Small RNA contracts for Alzheimer's disease
MX2018015397A (es) Co-cristales de benzoato de sodio y sus usos.
EP3429569A4 (en) METHOD FOR PREVENTING OR TREATING PARKINSON'S DISEASE BY PARNY SYNTHESIS
LT3413870T (lt) Igmesinas, skirtas panaudoti alzheimerio ligos gydymui
BR112014024736A2 (pt) antagonista receptor de h3 para uso no tratamento de doença de alzheimer
BR112022008113A2 (pt) Formas sólidas de um modulador de receptor s1p
EA200701584A1 (ru) Органические соединения, применяемые для лечения болезни альцгеймера, их применение и способ получения
EP3981469A4 (en) THERAPEUTIC FOR GOUT OR HYPERURICEMIA